Delighted that #glofitamab pivotal data for DLBCL is now online @NEJM. 39.4% CR in patients with the most common aggressive #lymphoma, Fixed course, durable remissions, good safety profile, I hope this data changes practice for patients with R/R #DLBCL #ASH22 #lymsm @DocHutchings